Research map: The weight of the enemy: Tumor burden as a tumor‐agnostic prognostic marker and the limits of immunotherapy

Back to the article

Papers in this map

  1. The abscopal effect in patients with cancer receiving immunotherapy · Blessie Elizabeth Nelson · 2023 · 71 citations · Cited by this paper
  2. New data inform decision‐making for breast cancer surgeries · 2026 · Related
  3. High baseline tumor burden‐associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2‐STAT3‐PD‐L1 pathway · Zhaowei Wen · 2023 · 63 citations · Cited by this paper
  4. DELII: Ultralow‐dose nivolumab extended overall survival after prior systemic therapy · 2026 · Related
  5. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials · Shiraj Sen · 2018 · 42 citations · Cited by this paper
  6. Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B‐cell lymphoma, including the post‐CAR T‐cell therapy setting: A meta‐analysis · 2026 · Related
  7. On target methods to induce abscopal phenomenon for Off‐Target effects: From happenstance to happenings · Blessie Elizabeth Nelson · 2022 · 14 citations · Cited by this paper
  8. Most older patients with advanced cancer prioritize QOL over extending survival · 2026 · Related
  9. Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy · Aakash P. Desai · 2022 · 10 citations · Cited by this paper
  10. Demographic, birth, parental characteristics, and the risk of early‐onset colorectal cancer: A population‐based nested case‐control study in California · 2026 · Related
  11. Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial · Megan K. D. Othus · 2024 · 7 citations · Cited by this paper
  12. Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions · 2026 · Related
  13. Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609) · Paul Loren Swiecicki · 2026 · 1 citation · Cited by this paper
  14. First‐line CDK4/6 inhibitors fail to improve overall survival in advanced breast cancer · 2026 · Related
  15. HER2 ‐targeting zongertinib shows early activity in untreated advanced HER2 ‐mutant NSCLC · 2026 · Related
  16. EXPRESSION OF CONCERN: Prolyl Hydroxylase‐2 (PHD2) Exerts Tumor‐Suppressive Activity in Pancreatic Cancer† · 2026 · Related
  17. Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma · 2026 · Related

Source: OpenAlex (CC0)